Product

General Info
Ireland
eculizumab
300 MG / 30ML (10MG/ML) – (single dose vial)
Hospital
Upload
Regulatory Approval
Agency Indication Approval Date ODD Date
US (FDA) Indication A
Indication B		 2020/02/03
2020/02/01 		2020/02/03
2020/02/01
EU (EMA) Indication B 2020/02/03 2020/02/03
Japan (PMDA) Indication C 2020/02/03 2020/02/03
Prices
1,000 EUR
950 EUR
2019 Q1/2019 Q2/2019 Q3/2019 Q4/2019
100,000.00 EUR 1,000.00 EUR 1,020.00 EUR 980.00 EUR 1,000.00 EUR
2020 YTD Q1/2020 Q2/2020 Q3/2020 Q4/2020
16,000.00 EUR 1,000.00 EUR 1,020.00 EUR
1,200 EUR
700 EUR
SKU 1
Reimbursement Mechanism Channel Indication List Price Visible Net Price Non-Public Net Price In-Market Net Price Transfer Price Net Realized Price
Private Retail PNH 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR
Private Retail AHUS 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR
Public Hospital PNH 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR
Public Hospital AHUS 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR
SKU 2
Reimbursement Mechanism Channel Indication List Price Visible Net Price Non-Public Net Price In-Market Net Price Transfer Price Net Realized Price
Private Retail PNH 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR
Private Retail AHUS 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR
Public Hospital PNH 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR
Public Hospital AHUS 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR 0.00 EUR
PNH
Access Details
No
No plan to seek National reimbursement
Not applicable.
Planned
IPF (2019/10/24)
National, Regional
Free Text.
Edit
aHus
Access Details
Yes
Dossier submitted / Decision received
2020/01/06
2020/02/06
Fully reimbursed
-
2020/01/01
2021/01/01
HTA Assessment
2020/02/10
TBC
Restricted
National
Subpopulation, Treatment Center
-
Price Negotiation
Yes
2020/02/13
-
0.00
0.00
Managed Entry Agreements
Yes
No
Yes: Pending review.
No
Yes: Though this needs further review I think?
No
No
No
No
No
No
Edit

Figures shown are for the whole of the UK:

Soliris
  2019   Q1/2020 Q2/2020 Q3/2020 Q4/2020
Revenue 1,000.00 EUR  
Volume 30.00  
Net Realized Price (per vial) 45,000.00 EUR  
Figures shown are for the whole of the UK
Soliris: PNH
  2019   Q1/2020 Q2/2020 Q3/2020 Q4/2020
Revenue 0.00 EUR  
Volume 0.00  
Net Realized Price (per vial) 45,000.00 EUR